Product Info Summary
| SKU: | A07061-1 |
|---|---|
| Size: | 100 μg/vial |
| Reactive Species: | Mouse, Rat |
| Host: | Rabbit |
| Application: | WB, ELISA (Cap) |
Customers Who Bought This Also Bought
Product info
Product Name
Anti-OIF/Ogn Antibody Picoband®
SKU/Catalog Number
A07061-1
Size
100 μg/vial
Form
Lyophilized
Description
Boster Bio Anti-OIF/Ogn Antibody Picoband® catalog # A07061-1. Tested in ELISA, WB applications. This antibody reacts with Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Storage & Handling
Store at -20˚C for one year from date of receipt. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for six months. Avoid repeated freeze-thaw cycles.
Cite This Product
Anti-OIF/Ogn Antibody Picoband® (Boster Biological Technology, Pleasanton CA, USA, Catalog # A07061-1)
Host
Rabbit
Contents
Each vial contains 4mg Trehalose, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.
Clonality
Polyclonal
Isotype
Rabbit IgG
Immunogen
E. coli-derived mouse OIF recombinant protein (Position: A20-F298).
Cross-reactivity
No cross-reactivity with other proteins.
Reactive Species
A07061-1 is reactive to Ogn in Mouse, Rat
Observed Molecular Weight
34 kDa
Calculated molecular weight
34.0 kDa
Background of Ogn
Osteoglycin (also called mimecan), encoded by the OGN gene, is a human protein. This gene encodes a member of the small leucine-rich proteoglycan (SLRP) family of proteins. The encoded protein induces ectopic bone formation in conjunction with transforming growth factor beta and may regulate osteoblast differentiation. High expression of the encoded protein may be associated with elevated heart left ventricular mass.
Antibody Validation
Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.
Application & Images
Applications
A07061-1 is guaranteed for WB, ELISA (Cap) Boster Guarantee
Assay Dilutions Recommendation
The recommendations below provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user.
Western blot,0.1-0.5μg/ml
ELISA (Cap),1-5μg/ml
Validation Images & Assay Conditions
Click image to see more details
Western blot analysis of OIF using anti-OIF antibody (A07061-1).
Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours.
Lane 1: recombinant mouse OGN protein 1ng.
After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-OIF antigen affinity purified polyclonal antibody (Catalog # A07061-1) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for OIF at approximately 34KD. The expected band size for OIF is at 34KD.
Click image to see more details
Culture with OGN-overexpressing CAFs-derived conditioned medium inhibits ovarian cancer cell aggressiveness ( A – B ) The mRNA expression and protein levels of OGN were examined in CAFs and NFs by qRT-PCR and Immunoblotting, respectively. ( C – D ) SKOV3 and A2780 cells were co-cultured with CAFs- or NFs-derived conditioned medium (CAFs-CM/NFs-CM) and examined for the mRNA expression and protein levels of OGN in SKOV3 and A2780 cells by qRT-PCR and Immunoblotting, respectively. ( E – F ) OGN overexpression was achieved in CAFs by transducing OGN overexpression vector (OGN-OE); OGN overexpression was confirmed by qRT-PCR and Immunoblotting, respectively. Then, SKOV3 and A2780 cells were cultured in control medium (con-CM), CAFs-CM, NF-CM, CAFs (lv-NC)-CM, or CAFs (OGN-OE)-CM, and examined for cell viability by MTT assay ( G ); DNA synthesis capacity by EdU ( H ); cell invasion by Transwell with chambers pre-coated with Matrigel ( I ); the protein levels of E-cadherin, vimentin, p-mTOR, mTOR, p-Akt, and Akt by Immunoblotting ( J ). ** P < 0.01, compared with NFs or CAFs (NC) group; ## P < 0.01 compared with CAFs (NC)-CM group
Index in PubMed under a CC BY license. PMID: 38402185
Click image to see more details
miR-1290 directly targets OGN and inhibits OGN expression ( A ) Targetscan, miRDIP, and literature search methods were used to search for miRNAs that might target OGN and serve as oncogenic miRNAs, and two miRNAs (miR-223-3p and miR-1290) were obtained. ( B ) The expression of miR-223-3p and miR-1290was examined in CAFs and NFs by qRT-PCR. ( C – D ) miR-1290 overexpression or inhibition was achieved in CAFs by transducing miR-1290 mimics or inhibitor; miR-1290 overexpression or inhibition was confirmed by qRT-PCR and Immunoblotting, respectively. ( E ) CAFs were transduced with miR-1290 mimics or inhibitor and examined for the mRNA expression by qRT-PCR. ( F ) Wild- and mutant-type OGN luciferase reporter vectors (wt-OGN/mut-OGN) were constructed as described in the M&M section. Then, wt-OGN or mut-OGN was co-transduced into 293T cells with miR-1290 mimics/inhibitor; the luciferase activity was determined. ( G ) The expression and location of miR-1290 and OGN in CAFs and NFs were determined by FISH assay. miR-1290 (green), OGN (red). Scale bar = 20 μm. * P < 0.05, ** P < 0.01, compared with NC mimics; ## P < 0.01, compared with NC inhibitor
Index in PubMed under a CC BY license. PMID: 38402185
Click image to see more details
The miR-1290/OGN axis in CAFs modulates ovarian cancer cell aggressiveness SKOV3 and A2780 cells were cultured in CAFs co-transduced with miR-1290 mimics and OGN-OE and examined for cell viability by MTT ( A ); DNA synthesis capacity by EdU ( B ); cell invasion by Transwell with chambers pre-coated with Matrigel ( C ); the protein levels of E-cadherin, vimentin, p-mTOR, mTOR, p-Akt, and Akt by Immunoblotting ( D ). ** P < 0.01, compared with CAFs (NC + NC mimics)-CM group; ## P < 0.01 compared with CAFs (OGN-OE + miR-1290 mimics)-CM group
Index in PubMed under a CC BY license. PMID: 38402185
Click image to see more details
The miR-1290/OGN axis in CAFs modulates tumorigenic capacity of ovarian cancer cell in vivo Xenograft transplanted tumor models were established in nude mice by injecting a mixture of SKOV3 cells with CAFs or infected CAFs (infected with miR-1290 mimics or lv-OGN) and nude mice were separated into five groups ( n = 6 per group): the SKOV3 cells + CAFs group, the SKOV3 cells + CAFs (lv-NC + NC mimics) group, the SKOV3 cells + CAFs (lv-OGN + NC mimics) group, the SKOV3 cells + CAFs (lv-NC + miR-1290 mimics) group, the SKOV3 cells + CAFs (lv-OGN + miR-1290 mimics) group. ( A ) Images of the tumors in each group. ( B ) Tumor volumes were measured every five days from the 10th day of the experiment. ( C ) Tumor weight were determined at the 30th day. ( D – E ) The mRNA levels of OGN and miR-1290 in mice tumor tissues were detected by qRT-PCR. ( F ) Ki67 and Vimentin levels in tumor tissues were examined using IHC staining. Scale bar = 20 μm. ( G ) The protein levels of E-cadherin, vimentin, p-mTOR, mTOR, p-Akt, and Akt in tumor tissues were determined using immunoblotting. * P < 0.05, ** P < 0.01, compared between SKOV3 cells + CAFs group and SKOV3 cells + CAFs (lv-NC + NC mimics); ## P < 0.01 compared with SKOV3 cells + CAFs (lv-NC + NC mimics) group; && P < 0.01 compared with SKOV3 cells + CAFs (lv-OGN + miR-1290 mimics) group
Index in PubMed under a CC BY license. PMID: 38402185
Click image to see more details
Sandwich ELISA - Recombinant mouse OIF/Ogn protein standard curve.
Use in combination with reagents from Mouse OIF/Ogn ELISA Kit EZ-Set (DIY Antibody Pairs) (EZ1617).
Specific Publications For Anti-OIF/Ogn Antibody Picoband® (A07061-1)
Loading publications
Recommended Resources
Here are featured tools and databases that you might find useful.
- Boster's Pathways Library
- Protein Databases
- Bioscience Research Protocol Resources
- Data Processing & Analysis Software
- Photo Editing Software
- Scientific Literature Resources
- Research Paper Management Tools
- Molecular Biology Software
- Primer Design Tools
- Bioinformatics Tools
- Phylogenetic Tree Analysis
Customer Reviews
Have you used Anti-OIF/Ogn Antibody Picoband®?
Share your experimental results or join a short interview to earn up to $1,000 in product credits or other rewards.
0 Reviews For Anti-OIF/Ogn Antibody Picoband®
Customer Q&As
Have a question?
Find answers in Q&As, reviews.
Can't find your answer?
Submit your question
5 Customer Q&As for Anti-OIF/Ogn Antibody Picoband®
Question
Is there a BSA free version of anti-OIF/Ogn antibody A07061-1 available?
Verified Customer
Verified customer
Asked: 2020-01-06
Answer
I appreciate your recent telephone inquiry. I can confirm that some lots of this anti-OIF/Ogn antibody A07061-1 are BSA free. For now, these lots are available and we can make a BSA free formula for you free of charge. It will take 3 extra days to prepare. If you require this antibody BSA free again in future, please do not hesitate to contact me and I will be pleased to check which lots we have in stock that are BSA free.
Boster Scientific Support
Answered: 2020-01-06
Question
See attached the WB image, lot number and protocol we used for thoracic aorta using anti-OIF/Ogn antibody A07061-1. Please let me know if you require anything else.
Verified Customer
Verified customer
Asked: 2019-06-21
Answer
Thank you very much for the data. Our lab team are working to resolve this as quickly as possible, and we appreciate your patience and understanding! You have provided everything we needed. Please let me know if there is anything you need in the meantime.
Boster Scientific Support
Answered: 2019-06-21
Question
Is a blocking peptide available for product anti-OIF/Ogn antibody (A07061-1)?
Verified Customer
Verified customer
Asked: 2019-06-21
Answer
We do provide the blocking peptide for product anti-OIF/Ogn antibody (A07061-1). If you would like to place an order for it please contact support@bosterbio.com and make a special request.
Boster Scientific Support
Answered: 2019-06-21
Question
We appreciate helping with my inquiry over the phone. Here are the WB image, lot number and protocol we used for thoracic aorta using anti-OIF/Ogn antibody A07061-1. Let me know if you need anything else.
J. Zhang
Verified customer
Asked: 2017-02-22
Answer
We appreciate the data. You have provided everything we needed. Our lab team are working to resolve your inquiry as quickly as possible, and we appreciate your patience and understanding! Please let me know if there is anything you need in the meantime.
Boster Scientific Support
Answered: 2017-02-22
Question
We are currently using anti-OIF/Ogn antibody A07061-1 for mouse tissue, and we are content with the ELISA results. The species of reactivity given in the datasheet says mouse, rat. Is it likely that the antibody can work on goat tissues as well?
O. Miller
Verified customer
Asked: 2016-12-08
Answer
The anti-OIF/Ogn antibody (A07061-1) has not been validated for cross reactivity specifically with goat tissues, though there is a good chance of cross reactivity. We have an innovator award program that if you test this antibody and show it works in goat you can get your next antibody for free. Please contact me if I can help you with anything.
Boster Scientific Support
Answered: 2016-12-08


